Detail Data
Volume (24h): 385,038 shares
P/E Ratio: /
Forward P/E: -1.41
EPS: -0.94 USD
Forward EPS: -0.66 USD
Number of Shares: 40,000,000 shares
Market Capitalization: 37,272,000.00 USD

Dividend

Dividend Value
Dividend Amount According to our data, the company Iterum Therapeutics does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a buy recommendation for Iterum Therapeutics stock. The current number of analysts covering this company is 2. The highest target price is 9 USD, while the lowest target price is 5 USD. The median target valuation set by analysts is 7 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Iterum Therapeutics.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Iterum Therapeutics stock is: buy
Number of Analysts: 2
Highest Target Price: 9 USD
Lowest Target Price: 5 USD
Median Target Price: 7 USD

Fundamental Indicators

Indicator Data
Total Revenue: /
Net Income: -22,564,000.00 USD
Price-to-Book (P/B): /
PEG Ratio: /
Exchange: NasdaqCM
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 9
Country: Ireland

Where to Buy Iterum Therapeutics Stock?

You can purchase Iterum Therapeutics stock on the NasdaqCM under the ticker symbol: ITRM. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Iterum Therapeutics Stock

Indicator Value
Company Revenue: -
EBITDA: -15,617,000.00 USD - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -0.94 USD
Book Value Per Share: -0.07 USD
Total Cash: 12,652,000.00 USD
Total Cash per Share: 0.32 USD
Total Debt: 32,045,000.00 USD
Debt to Equity Ratio: -
Quick Ratio 3.49
Current Ratio 3.73
Free Cash Flow -10,694,500.00 USD
Operating Cash Flow -16,747,000.00 USD
Gross Margins -
EBITDA Margins -
Operating Margins -
Profit Margins -
Return on Assets -38.6 %
Return on Equity -
Earnings Growth (1 year) -
Revenue Growth (1 year) -
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 37,272,000.00 USD
Enterprise Value 56,665,000.00 USD
EV/Revenue -
EV/EBITDA -3.628
Float Shares 39,254,000 shares
Shares Outstanding 40,000,000 shares
Held Percent Insiders 0.01 %
Held Percent Institutions 6.41 %
Shares Short 1,042,872
Shares Short Prior Month 1,497,165
Date Short Interest 2025-04-30
Short Percentage of Total Shares 3.02 %
Short Ratio 2.40
Beta 2.91
Short Percentage of Float 3.08 %
Implied Shares Outstanding 35,598,500

Frequently Asked Questions (FAQ)

According to our data, the company Iterum Therapeutics does not pay dividends yet, even in 2025.

Iterum Therapeutics shares are traded on the NasdaqCM stock exchange under the ticker: ITRM. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Iterum Therapeutics shares is from a total of 2 analysts. The average target price prediction is 7 USD per share.

The total number of Iterum Therapeutics shares on the exchange is 40,000,000.00 shares, which at the current market capitalization gives the company a total valuation of 37,272,000.00 USD.